Summary The aim of this study was to assess relationships between Bcl-2 expression, response to chemotherapy and a number of pathological and biological tumour parameters in premenopausal, lymph node-negative breast cancer patients. Expression of Bcl-2 was determined using immunohistochemistry on paraffin-embedded sections in a series of 441 premenopausal, lymph node-negative breast cancers of patients randomised to receive perioperative chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide) or no perioperative chemotherapy. Immunohistochemistry of Bcl-2 was evaluated by scoring both staining intensity (0-3) and number of positive cells (0-2). Using these scores tumours were grouped into categories 0-6. It was found that 9.2% of the tumours were completely negative (0), 17.2% weakly (1 + 2), 41.6% moderately (3 + 4) and 31.9% strongly positive (5+6) for Bcl-2. A positive correlation was found between high Bcl-2 expression and oestrogen (P<0.001) and progesterone receptor positivity (P<0.001) and low tumour grade (P<0.001), whereas high Bcl-2 expression was negatively correlated with p53 (P<0.001) and c-erb-B-2 positivity (P<0.001), high Ki-67 index (P<0.001), mitotic index (P<0.001) and large tumour size (P=0.006). Patients with tumours expressing high levels of Bcl-2 (overall score 3-6) had a significantly better disease-free (P=0.004) and overall (P=0.009) survival. However, in a multivariate model this association no longer remained significant. There was a trend for an effect of adjuvant chemotherapy on disease-free survival both for patients with Bcl-2-positive (HR-0.61, 95% CI 0.35-1.06, P=0.07) and negative (HR=0.55, 95% CI 0.27-1.12, P=0.09) breast tumours at a median follow-up of 49 months. The level of Bcl-2 expression does not seem to predict response to perioperative chemotherapy in premenopausal, lymph node-negative breast cancer patients. High levels of Bcl-2 are preferentially expressed in well-differentiated tumours and are associated with favourable prognosis. However, Bcl-2 expression is not an independent prognostic factor in this patient series.
The product of the bcl-2 gene has been shown to protect cells against cell death induced by a myriad of insults, including most chemotherapeutic drugs (Reed, 1994) . For this reason, it has been hypothesised that bcl-2 overexpression may play a role in resistance to chemotherapy, as has recently been demonstrated for neuroblastomas (Castle et al., 1993) and acute myeloid leukaemia (Campos et al., 1993) .
Bcl-2 is present in mature lymphoid cell populations, in long-lived post-mitotic cells (e.g. neurons), in complex organised epithelia (e.g. skin, gastrointestinal mucosa) and in glandular epithelium under hormonal and growth factor control (e.g. thyroid, prostate, uterus and breast) (Hockenbery et al., 1991; Gompel et al., 1994) .
The bct-2 gene is a member of a gene family, which includes bcl-X (74% homology) (Boise et al., 1993) and bax (21% homology) (Oltvai et al., 1993) . Bcl-2 immunoreactivity was demonstrated to be confined to the mitochondrial outer circumference and the nuclear envelope and to a lesser degree to the cell membrane (De Jong et al., 1994) . The cellular mechanism by which Bcl-2 protein functions has not yet been elucidated, but recent data suggest that heterodimerisation with Bax proteins is important (Yin et al., 1995) . Furthermore, it has recently been reported that bcl-2 expression is inhibited by the product of the p53 tumoursuppressor gene (Haldar et al., 1994; Miyashita et al., 1994; Selvakumaran et al., 1994) , an important determinant in the induction of apoptosis (Merritt et al., 1994; Lowe et al., 1993; Zhu et al., 1994; Debbas and White, 1993) .
Bcl-2 has been shown to be frequently expressed in breast cancer. Leek et al. (1994) reported a strong correlation between the presence of Bcl-2 (72/111 positives) and oestrogen receptor (ER) positivity in a series of 111 breast cancers; no relationship was found with lymph node status, tumour size or differentiation type and an inverse relationship with immunostaining of p53 and c-erbB-2 proteins respectively. Similar findings were recently reported by Silvestrini et al. (1994) ; in a series of 283 breast cancers from lymph nodenegative patients, the highest fraction of Bcl-2 positive cells was found in small, ER-positive, slowly proliferating and p53-negative tumours and a stronger association was seen between Bcl-2 and p53 than between these variables and proliferative activity. Bcl-2 predicted 6 year relapse-free and overall survival, but its prognostic value seemed to mainly depend on p53 expression. Bhargava et al. (1994) 
Materials and methods Patients
All 441 premenopausal women with node-negative early breast cancer were drawn from a large prospectively randomised adjuvant trial (EORTC Trial 10854), comparing surgery followed by perioperative chemotherapy vs surgery alone. The eligibility criteria for this trial have been described previously (Clahsen et al., 1994b Statistics Statistical analyses were performed using SAS-software (SAS Institute, Cary, NC, USA). Disease-free survival was defined as the time interval between date of randomisation and date of disease progression (including secondary primary cancer and contralateral breast cancers) or death, whichever came first. Locoregional recurrence was defined as a recurrence in the homolateral breast or in homolateral regional lymph nodes. Contralateral breast cancer was considered as a secondary primary cancer and supraclavicular lymph node metastases were evaluated as being distant metasases. Differences in distribution of tumour parameters among groups of patient characteristics were tested for using the chisquare test. For analysis of the prognostic value of Bcl-2 expression on disease-free and overall survival, patients were divided into two groups with low (0,1,2) or moderate to high expression (3,4,5,6). Survival curves were estimated using the Kaplan-Meier technique (Kaplan and Meier, 1958) . Differences in the duration of survival were compared using a twosided log-rank test (Mantel, 1966) . The proportional hazards regression model (Cox, 1972) was used for multivariate analysis. All P-values reported are two-sided.
Results

Expression of Bct-2 in normal breast tissue and apocrine metaplasia
Within breast tissue of premenopausal women, pronounced differences in Bcl-2 staining intensity were observed between lobular ducts and intralobular ducts. In most cases intralobular ducts stained strongly positive for Bcl-2 (Figure la). Lobular ducts showed remarkable variability in staining intensity between different breasts and even different lobules within the same breast ( Figure lb) . On a cellular level this heterogeneity in Bcl-2 expression was even more pronounced: Figure lc shows an example of cells with strong cytoplasmic staining scattered among cells that are very weakly stained. Intralobular ducts generally showed strong, homogeneous expression of Bcl-2. Luminal epithelial cells typically expressed higher levels of Bcl-2 than myoepithelial cells, but in some cases this expression pattern appeared to be reversed. Apocrine metaplastic epithelium was observed in ten sections and stained invariably negative for Bcl-2 ( Figure ld) . In general, Bcl-2 immunoreactivity in breast epithelial cells showed granular staining of the cytoplasm, suggestive of localisation to cellular organelles, and strong perinuclear staining. This is in line with previous publications on Bcl-2 localisation (De Jong et al., 1994 Missing 18 Total 441 100.0 SI, staining intensity, range of scores 0-3; F, fraction of positive tumour cells, fraction of cells in each category: 0-25% = 0, 25-75% = 1, 75 -100% = 2. Tumours were grouped into separate categories, not by addition or multiplication of the two scores, but by classifying them according to the fraction of cells showing the most intense staining. Tumours that had the same (SI), but also contained a significant number of tumour cells with less intense staining (score F = 0 or F = 1) were grouped together. This scoring system resulted in Bcl-2 scores ranging from 0 to 6. - (Table II) . Bcl-2 was negatively correlated with large tumour size (P=0.006) (Figure 2b ), p53 (P<0.001) (Figure 2d ) and cerbB2 positivity (P<0.001) (Figure 2f ), high (P<0.001) (Figure 2e ) and high mitotic index (P<0.001) (data not shown). No correlation was found with patient age.
Bcl-2 expression and DFS and OS For statistical analysis of the prognostic value of Bcl-2 expression for DFS and OS, best separation of survival curves was obtained when patients were divided into two groups: undetectable or low expression (0-2) and moderate to high expression (3-6) of Bcl-2. Patients with tumours expressing high levels of Bcl-2 (overall score 3-6) had a significantly better DFS (P = 0.004) (Figure 3a ) and OS (P = 0.009) (Figure 3b) (Figure 3c and Table III ) and moderate or high (Figure 3d and Table  III ) Bcl-2 expression. As can be seen, the response to adjuvant chemotherapy is similar for Bcl-2-negative and Bcl-2-positive tumours, indicating that Bcl-2 does not predict response to perioperative chemotherapy in premenopausal, lymph node-negative patients. Similarly, when all patients with p53-positive tumours were omitted from the analysis, Bcl-2 did not seem to predict response to chemotherapy (data not shown).
Discussion
Adjuvant chemotherapy has been demonstrated to prolong survival in lymph node-negative breast cancer patients (Early Breast Cancer Trialists' Collaborative Group, 1992). However, the treatment effect is relatively small and selective use of chemotherapy will be necessary to maximise the benefit to individual patients. Thus, an important clinical problem is the selection of those lymph node-negative patients that will benefit from adjuvant chemotherapy. At present, no useful biological markers able to predict response to chemotherapy are available. In this study, we assessed relationships between Bcl-2 expression and patient survival, response to adjuvant chemotherapy and a number of clinicopathological parameters in a series of 441 premenopausal, node-negative breast cancer patients. Bcl-2 has been reported to be frequently expressed in breast cancer and to be associated with favourable clinicopathological parameters and favourable prognosis in node-negative and node-positive breast cancers (Silvestrini et al., 1994; Joensuu et al., 1994) . In women with node-positive breast cancer, Bcl-2 positivity was associated with favourable outcome in patients treated with adjuvant chemotherapy and/ or hormone therapy (Gasparini et al., 1995; Gee et al., 1994; Hellemans et al., 1995) . However, because all patients in these studies received adjuvant therapy, it was not possible to determine whether high expression of Bcl-2 truly predicted responsiveness or if it was merely a marker of good prognosis.
In the present study, analysis of patient survival data demonstrated that premenopausal, node-negative breast cancer patients with tumours expressing moderate to high levels of Bcl-2 had a significantly longer DFS and OS ( Figure  3a and 3b) . However, in multivariate analysis Bcl-2 was not found to be an independent prognostic factor, a finding similar to that recently reported by Silvestrini et al. (1994) and Joensuu et al. (1994) Response to perioperative chemotherapy did not differ significantly among patients whose tumours expressed either undetectable to low or moderate to high levels of Bcl-2 ( Figure 3c and 3d and Table III ). These findings demonstrate that although moderate to high expression of Bcl-2 is a marker of favourable prognosis, Bcl-2 does not seem to predict response to adjuvant chemotherapy in this series of premenopausal, node-negative breast cancer patients. One may argue that only one cycle of perioperative chemotherapy cannot be considered an adequate treatment to assess the relationship between Bcl-2 expression and response to chemotherapy. However, the adjuvant chemotherapy regimen used in this trial can be described as a fairly intensive course of polychemotherapy. This regimen of perioperative chemotherapy resulted in a relatively small, but significant increase in DFS and OS in the group of premenopausal, lymph node-negative patients. Moreover, the benefit obtained with the single course of FAC used in this trial, was similar to results obtained with more prolonged administration of adjuvant chemotherapy in lymph node-negative patients (Early Breast Cancer Trialists' Collaborative Group, 1992) .
In this respect, it seems unlikely that the failure of Bcl-2 to predict response to chemotherapy in node-negative patients can be contributed to the treatment regimen used in this trial.
In addition, it is important to note that the 'perioperative' chemotherapy, was given within 24 h after surgery and thus did not affect the expression level of Bcl-2.
An important finding, with respect to the association of high expression of Bcl-2 with improved survival, was the strong correlations observed between Bcl-2 expression and a number of important clinicopathological parameters ( Figure  2a -f) . High expression of Bcl-2 was positively correlated with well-differentiated tumours and low tumour grade and with ER and PgR positivity. High Bcl-2 expression was negatively correlated with p53 and c-erbB-2 positivity, with high MIB-1 (Ki-67) index and high mitotic index and with large tumour size. Thus, expression of Bcl-2 was associated with the presence of a number of classical prognostic factors known to predict a lower risk of relapse, providing a likely explanation for the improved survival of patients with tumours expressing high levels of Bcl-2.
An important finding, with regard to the failure of Bcl-2 to predict responsiveness, seemed to be the strong negative correlation between Bcl-2 expression and p53 protein accumulation, in concordance with recent reports by other groups (Leek et al., 1994; Silvestrini et al., 1994; Joensuu et al., 1994; Gasparini et al., 1995) . Recently, evidence has been obtained that wild-type as well as most mutant p53 proteins can down-regulate Bcl-2 expression in vitro and in vivo (Haldar et al., 1994; Selvakumaran et al., 1994; . Mutations in the p53 tumour-suppressor gene are a marker of poor prognosis in node-negative breast cancer (Isola et al., 1992) and experimental data have demonstrated increased resistance to doxorubicin and gamma irradiation in tumours lacking functional p53 (Lowe et al., 1994) . We also evaluated the predictive value of Bcl-2 expression on responsiveness in the subgroup of patients with p53-negative tumours. Again, Bcl-2 did not seem to predict response to chemotherapy. Thus, the failure of Bcl-2 to predict response to chemotherapy is not the result of the relatively high percentage of p53-positive tumours in the group of patients with negative to low expression of Bcl-2.
It should be realised that bcl-2 is only one member of an expanding family of genes involved in cell death regulation, including bcl-X (Boise et al., 1993 ), mcl-i (Reynolds et al., 1994 ), al (Lin et al., 1993 ), bax (Oltvai et al., 1993 , bad (Yang et al., 1995) and bak (Kiefer et al., 1995) , that have not yet been studied in human cancer. The proteins encoded by these genes can bind to each other, forming homodimers and heterodimers, as well as physically interact with a number of other proteins. Co-expression of these proteins can either decrease or increase the cellular threshold for induction of apoptosis set by Bcl-2, and may explain the failure of Bcl-2 to predict responsiveness in this series of patients.
The observation that Bcl-2 is preferentially expressed in well-differentiated tumours is in line with data on Bcl-2 expression in other types of solid tumours (e.g. non-small cell lung cancer and thyroid carcinoma) (Pezzella et al., 1993; Pilotti et al., 1994) . In thyroid carcinoma, bcl-2 appeared to be under the control of differentiation-related transcription factors (Civitareale et al., 1989) . The data presented in this study suggest the presence of a similar differentiationdependent regulation of bcl-2 in breast epithelium. This hypothesis is supported by the strong positive correlations found between high Bcl-2 expression and ER postivity. Of interest, in this context, is that all observed cases of apocrine metaplasia were found to be completely negative for both Bcl-2 ( Figure Id) and ER (data not shown). These findings indicate that in breast epithelium Bcl-2 expression is under the control of oestrogen. Data on Bcl-2 expression in normal breast tissue and endometrium during the menstrual cycle support the hypothesis that bcl-2 gene expression is hormonally regulated Gompel et al., 1994) .
Bd-2 ixprsm rnIcer x0 HJ van SkKctn et i OA A DCIS component was present in 65.5% of the cases and mostly showed a similar Bcl-2 expression as the invasive component (only 20.5% was judged to have a stronger or weaker staining intensity), suggesting that clonal variations in Bcl-2 expression are a relatively early event in tumour progression.
In conclusion, this study confirms that Bcl-2 is a strong, but not an independent marker of favourable prognosis and demonstrates that it has little predictive value for response to a single course of polychemotherapy in premenopausal, nodenegative breast cancer patients.
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BC, breast cancer; ER, oestrogen receptor, PgR, progesterone receptor; F, 5-fluorouracil; A, doxorubicin; C, cyclophosphamide; PBS, phosphate-buffered saline; BSA, bovine serum albumin; DFS, disease-free survival; OS, overall survival; SI, staining intensity; DCIS, ductal carcinoma in situ; HR, hazard ratio; CI, confidence interval; PeCT, perioperative chemotherapy; N, total number of patients; 0, number of events.
